Education, Science, Technology, Innovation and Life
Open Access
Sign In

Exploring the therapeutic effect of Qijia Wuling soupon cardiomyocyte mast cells

Download as PDF

DOI: 10.23977/medcm.2024.060206 | Downloads: 14 | Views: 199


Ma Chao 1, Zhi Liqin 2


1 Shaanxi University of Chinese Medicine, Xianyang, 712046, China
2 Affiliated Hospital of Integrated Traditional and Western Medicine of Shaanxi University of Chinese Medicine, Xi'an, 710000, China

Corresponding Author

Zhi Liqin


The formation of cardiac hypertrophy is an important pathological change leading to chronic heart failure, which determines the development and prognosis of CHF. When the heart is damaged and stressed, the cardiomyocytes become hypertrophic and lead to changes in cellular metabolic patterns, which ultimately affect the structure and function of the heart. Qijia Wuling soup is the experience prescription of treating heart failure by the chief physician of Staff Liqin. In this study, we found that it could improve the echocardiographic parameters and relieve the symptoms of CHF in rats. In this study, the effect and mechanism of Qijia Wuling soup on myocardial hypertrophy in rats with CHF were investigated on the basis of the previous studies which proved that Qijia Wuling soup was effective in the treatment of CHF, to provide evidence for improving cardiac hypertrophy. H9C2 cells were inoculated into 6-well plate and randomly divided into control group and model group. Study it. This study demonstrated that qjwlt-containing serum had a significant protective effect on H9C2 cardiomyocytes injury induced by (-)-noradrenaline. This provides an important experimental and theoretical basis for the clinical application of qjwlt in the treatment of heart failure and improvement of cardiac hypertrophy. With the in-depth study of its mechanism of action, Qijia Wuling soupis expected to become one of the effective drugs in the treatment of CHF, bringing better therapeutic effect and quality of life for patients.


Qijia Wuling soup; CHF; cardiac hypertrophy; BNP; ANP; AKT1


Ma Chao, Zhi Liqin, Exploring the therapeutic effect of Qijia Wuling soupon cardiomyocyte mast cells. MEDS Chinese Medicine (2024) Vol. 6: 48-55. DOI:


[1] Chimed S, van der Bijl P, Lustosa R, Fortuni F, Montero-Cabezas JM, Ajmone Marsan N, Gersh BJ, Delgado V, Bax JJ. Functional classification of left ventricular remodelling: prognostic relevance in myocardial infarction. ESC Heart Fail. 2022 Apr;9(2):912-924. doi: 10.1002/ehf2.13802. Epub 2022 Jan 22. PMID: 35064777; PMCID: PMC8934947.
[2] Kim Y. Interaction between beta blockers and epinephrine on hemodynamics of spontaneously hypertensive rats. Res Commun Chem Pathol Pharmacol. 1993 Apr;80(1):3-19. PMID: 8488340.
[3] Saha A, Ahmed S. The Link between Heat Shock Proteins, Renin-Angiotensin System, and the Coagulation Cascade in the Pathogenesis of the Coronavirus-19 Disease. Adv Exp Med Biol. 2023; 1409:161-171. doi: 10.1007/5584_2022_735. PMID: 35882774.
[4] Coutinho T. Arterial stiffness and its clinical implications in women. Can J Cardiol. 2014 Jul; 30(7):756-764. doi: 10.1016/j.cjca.2014.03.020. Epub 2014 Mar 20. PMID: 24970788.
[5] Gebauer AM, Pfaller MR, Braeu FA, Cyron CJ, Wall WA. A homogenized constrained mixture model of cardiac growth and remodeling: analyzing mechanobiological stability and reversal. Biomech Model Mechanobiol. 2023 Dec; 22(6):1983-2002. doi: 10.1007/s10237-023-01747-w. Epub 2023 Jul 23. PMID: 37482576; PMCID: PMC10613155.
[6] Vranckx P. European Heart Journal - Acute Cardiovascular Care moving onwards and upwards. Eur Heart J Acute Cardiovasc Care. 2021 Mar 5;10(1):1-2. doi: 10.1093/ehjacc/zuaa040. PMID: 33721019.
[7] Fielitz J, Philipp S, Herda LR, Schuch E, Pilz B, Schubert C, Günzler V, Willenbrock R, Regitz-Zagrosek V. Inhibition of prolyl 4-hydroxylase prevents left ventricular remodelling in rats with thoracic aortic banding. Eur J Heart Fail. 2007 Apr;9(4):336-342. doi: 10.1016/j.ejheart.2006.10.006. Epub 2006 Dec 4. PMID: 17145199.
[8] Guglin M, Kristof-Kuteyeva O, Novotorova I, Pratap P. Aldosterone antagonists in heart failure. J Cardiovasc Pharmacol Ther. 2011 Jun;16(2):150-159. doi: 10.1177/1074248410387606. Epub 2010 Dec 15. PMID: 21160084.
[9] Albert NM, Yancy CW, Liang L, Zhao X, Hernandez AF, Peterson ED, Cannon CP, Fonarow GC. Use of aldosterone antagonists in heart failure. JAMA. 2009 Oct 21;302(15):1658-1665. doi: 10.1001/jama.2009.1493. PMID: 19843900.
[10] Zhang L, Yan K, Zhao H, Shou Y, Chen T, Chen J. Therapeutic effects and safety of early use of sacubitril/valsartan after acute myocardial infarction: a systematic review and meta-analysis. Ann Palliat Med. 2022 Mar; 11(3):1017-1027. doi: 10.21037/apm-22-210. PMID: 35365031.
[11] Nichols S, McGregor G, Breckon J, Ingle L. Current Insights into Exercise-based Cardiac Rehabilitation in Patients with Coronary Heart Disease and Chronic Heart Failure. Int J Sports Med. 2021 Jan;42(1):19-26. doi: 10.1055/a-1198-5573. Epub 2020 Jul 10. PMID: 32650344.
[12] Metra M, Giubbini R, Nodari S, Boldi E, Modena MG, Dei Cas L. Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation. 2000 Aug 1;102(5):546-551. doi: 10.1161/01.cir.102.5.546. PMID: 10920067.
[13] Musse M, Lau JD, Yum B, Pinheiro LC, Curtis H, Anderson T, Steinman MA, Meyer M, Dorsch M, Hummel SL, Goyal P. Physician Perspectives on the Use of Beta Blockers in Heart Failure With Preserved Ejection Fraction. Am J Cardiol. 2023 Apr 15;193:70-74. doi: 10.1016/j.amjcard.2023.01.050. Epub 2023 Mar 4. PMID: 36878055; PMCID: PMC10114214.
[14] Niriayo YL, Asgedom SW, Demoz GT, Gidey K. Treatment optimization of beta-blockers in chronic heart failure therapy. Sci Rep. 2020 Sep 28;10(1):15903. doi: 10.1038/s41598-020-72836-4. PMID: 32981932; PMCID: PMC7522285.
[15] Banerjee D, Rosano G, Herzog CA. Management of Heart Failure Patient with CKD. Clin J Am Soc Nephrol. 2021 Jul; 16(7):1131-1139. doi: 10.2215/CJN.14180920. Epub 2021 Jan 25. PMID: 33495289; PMCID: PMC8425606.
[16] Álvarez-Zaballos S, Martínez-Sellés M. Angiotensin-Converting Enzyme and Heart Failure. Front Biosci (Landmark Ed). 2023 Jul 26;28(7):150. doi: 10.31083/j.fbl2807150. PMID: 37525924.
[17] Lee S, Kim H, Woo Yim H, Hun-Sung K, Han Kim J. Comparison of cardiocerebrovascular disease incidence between angiotensin converting enzyme inhibitor and angiotensin receptor blocker users in a real-world cohort. J Appl Biomed. 2023 Apr;21(1):7-14. doi: 10.32725/jab.2023.002. Epub 2023 Mar 27. PMID: 37016775.
[18] Jurin, Hong Mei. Advances in the research of Shakubatroxel Valsartan in the treatment of cardiovascular diseases [J]. Chinese Journal of multiple organ diseases of the elderly, 2020, 19(05) : 384-387.
[19] Yi-Meng, G.U., et al., Meta-analysis of statin combined with trimetazidine on the regulation of inflammatory factors in coronary atherosclerotic heart disease and improvement of ventricular remodeling. Hainan Medical College Journal: English edition, 2023. 29(3): p. 60-66.
[20] Warwick. Current status and development trend of non-drug therapy for heart failure [J]. Chinese Journal of Medicine, 2006, (16): 1083-1085.
[21] Sanz-Ruiz R, Fernández-Avilés F. Autologous and allogeneic cardiac stem cell therapy for cardiovascular diseases. Pharmacol Res. 2018 Jan; 127:92-100. doi: 10.1016/j.phrs.2017.05.024. Epub 2017 May 26. PMID: 28554583.
[22] Zhang H, Xue Y, Pan T, Zhu X, Chong H, Xu C, Fan F, Cao H, Zhang B, Pan J, Zhou Q, Yang G, Wang J, Wang DJ. Epicardial injection of allogeneic human-induced-pluripotent stem cell-derived cardiomyocytes in patients with advanced heart failure: protocol for a phase I/IIa dose-escalation clinical trial. BMJ Open. 2022 May 6; 12(5):e056264. doi: 10.1136/bmjopen-2021-056264. PMID: 35523485; PMCID: PMC9083430. 

Downloads: 4729
Visits: 197579

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.